Bristol Myers Squibb Reports 6% YOY Revenue Growth in Q1 2024, Driven by Eliquis and Reblozyl
Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has reported a 6% year-on-year (YOY) increase...
Roche’s Q1 2024 Turnover Rises 2% YOY, Driven by New Medicines and Diagnostics
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has reported a 2% year-on-year (YOY) increase...
Gan & Lee Pharmaceuticals Reports 52.31% YOY Revenue Growth in 2023, Driven by Insulin Sales
Gan & Lee Pharmaceuticals (SHA: 603087) has announced its financial results for 2023, reporting a...
Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly...
Insilico Medicine Partners with invoX Pharma to Boost AI-Driven Drug Discovery
China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with...
Hebei Changshan Biochemical’s Albenatide File for Type 2 Diabetes Accepted by China’s NMPA
Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) has announced that the National Medical...
Betta Pharmaceuticals’ BPI-16350 Combo Therapy Shows Improved PFS in Breast Cancer Trial
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced an update on its Phase III...
MicroPort MedBot Reports 384.2% YOY Revenue Increase in 2023, Driven by Robotic Surgical Devices
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced its financial results for 2023,...
Novartis’s Lutathera Secures FDA Approval for Pediatric Gastroenteropancreatic NETs
The US Food and Drug Administration (FDA) has granted regulatory approval to Novartis (NYSE: NVS)...
Hubei Province Issues Anti-Commercial Bribery Guidelines for Medical Industry
The Hubei provincial market supervision administration has released a set of guidelines titled “Anti-Commercial Bribery...
Shanghai Junshi Biosciences’ PD-1 Inhibitor Toripalimab Files for Two Indications in Hong Kong
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the Hong Kong...
Abbisko Therapeutics’ Irpagratinib Earns Orphan Drug Designation from US FDA for Hepatocellular Carcinoma
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has received Orphan Drug Designation (ODD)...
Jenscare Scientific’s LuX-Valve Fails to Gain Approval from China’s CDME
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...
MSD Partners with Hanmi Pharmaceutical to Develop Combination Therapy for Solid Tumors
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with South Korea’s Hanmi...
Sichuan Kelun Pharmaceutical Reports 12.69% YOY Revenue Growth in 2023 Financial Results
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a leading pharmaceutical company in China, has announced...
China Unveils 16-Measure Policy to Support Overseas Investment in Domestic Tech Firms
A coalition of 10 Chinese government bureaus, including the Ministry of Commerce, Ministry of Foreign...
Sanofi’s Rilzabrutinib Meets Primary Endpoint in Phase III ITP Trial
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its Phase III trial for rilzabrutinib,...
China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises
The China Securities Regulatory Commission (CSRC) has introduced a comprehensive set of 16 measures aimed...
Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant...
Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released...